355P The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer (mCRC) patients: A Turkish oncology group (TOG) study

Abstract

All RAS wild-type metastatic colorectal cancer patients do not have the same benefit from the anti-epidermal growth factor receptor (EGFR) therapies. Studies have shown that nuclear factor-kB (NF-kB), hypoxia-inducible factor-1α (HIF-1α), interleukin 8 (IL-8) and transforming growth factor β (TGF-β) may be therapeutic targets for metastatic colorectal cancers. We aimed to clarify the prognostic value of NF-κB, HIF-1α, IL-8 and TGF-β expression in patients receiving EGFR inhibitors in left sided mCRC patients.